ADIPOQ and type 2 diabetes mellitus: These prospective studies have revealed that low adiponectin levels to be predictive of the development of new cardiovascular events in patients with CKD, including the hemodialysis population [9-11] While adiponectin has been shown to predict the development of type 2 diabetes in renal transplant recipients [12], there is yet to date any published data on the association between adiponectin and CVD in RTR.